SWANBIO THERAPEUTICS
SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders.
SWANBIO THERAPEUTICS
Industry:
Biotechnology
Founded:
2017-01-01
Address:
Bala Cynwyd, Pennsylvania, United States
Country:
United States
Website Url:
http://www.swanbiotx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
118 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps Content Delivery Network Global Site Tag Nginx
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on genetic diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Syncona Partners LLP
Syncona Partners LLP investment in Venture Round - SwanBio Therapeutics
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series B - SwanBio Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series B - SwanBio Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series A - SwanBio Therapeutics
Partners Innovation Fund
Partners Innovation Fund investment in Series A - SwanBio Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Seed Round - SwanBio Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-06-01 | SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer |
Official Site Inspections
http://www.swanbiotx.com
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SwanBio Therapeutics"
About - SwanBio Therapeutics
Board of Directors | SwanBio Therapeutics
Board of Directors. Our Board of Directors is deeply invested in SwanBio’s mission. Their experience, expertise, and alignment with SwanBio’s core values provides additional strength to the company's continued growth and clinical …See details»
SwanBio Evolves Leadership Team with Appointment of Executive …
Oct 16, 2023 SwanBio is supported by long-term, committed investment partners, including its primary investors Syncona, Ltd. and Mass General Brigham Ventures. For more information, …See details»
SwanBio Evolves Leadership Team with Appointment …
Oct 16, 2023 “On behalf of both SwanBio and Syncona, I want to express our sincere gratitude to Tom for his steadfast leadership and vital contributions to the organization during his four-year tenure, and ...See details»
SwanBio Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological …See details»
SwanBio Therapeutics - LinkedIn
SwanBio Therapeutics | 6,409 followers on LinkedIn. Researching & developing leading-edge gene therapies to deliver dramatic clinical efficacy for neurological diseases | SwanBio is now part of ...See details»
SwanBio Therapeutics - VentureRadar
"SwanBio Therapeutics is a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions.See details»
SwanBio Evolves Leadership Team with Appointment of Executive …
PHILADELPHIA, October 16, 2023 – SwanBio Therapeutics, a gene therapy company developing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today …See details»
SwanBio Therapeutics Company Overview, Contact Details
Oct 4, 2023 [email protected]: [email protected]: 98%. [email protected]: [email protected]: 1%. [email protected]: [email protected]: 1%. See more …See details»
SwanBio Therapeutics Announces $56 Million Series B Financing to ...
May 18, 2022 For more information, visit SwanBioTx.com. Media Contact: Lara Furst +1-703-946-0183. [email protected] Investor Contact: Chelcie Lister +1-910-777-3049. …See details»
SwanBio Therapeutics Announces FDA Investigational New Drug …
Jan 25, 2022 For more information, visit SwanBioTx.com. Contacts Media: Lara Furst 703-946-0183 [email protected] Investor: Chelcie Lister 910-777-3049 [email protected]See details»
FDA Grants Orphan Drug Designation to SBT101, the First
Mar 15, 2022 SwanBio Therapeutics to initiate Phase 1/2 trial later this year. Currently no approved treatments for AMN. PHILADELPHIA, March 15, 2022 – SwanBio Therapeutics, a …See details»
Our Approach - SwanBio Therapeutics
SwanBio collaborates with international key leaders as well as academic institutions and other research organizations to advance the company’s portfolio. For more information about …See details»
SwanBio Therapeutics - Overview, News & Similar companies
SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women PHILADELPHIA--(BUSINESS WIRE)--SwanBio Therapeutics, …See details»
SwanBio Evolves Leadership Team with Appointment of Executive …
Oct 16, 2023 PHILADELPHIA--(BUSINESS WIRE)-- SwanBio Therapeutics, a gene therapy company developing AAV-based therapies for the treatment of devastating, inherited …See details»
SwanBio Therapeutics
May 28, 2021 The annual award recognizes a Pennsylvania-based company or organization of 100 employees or fewer that has experienced significant growth and/or achievement, while …See details»
SwanBio Therapeutics Announces $56 Million Series B Financing to ...
May 18, 2022 Media Contact: Lara Furst +1-703-946-0183 [email protected] Investor Contact: Chelcie Lister +1-910-777-3049 [email protected] Patient and Physician …See details»
SwanBio Therapeutics Announces FDA Investigational New Drug
Jan 25, 2022 SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced …See details»
Our Focus - SwanBio Therapeutics
Historically, neurological disorders have presented a unique challenge for drug development. Creating safe and effective drugs for diseases involving the spinal cord requires identifying …See details»